The Top 5 Biosimilar Articles for the Week of April 11

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of April 11, 2022.

Number 5: White bagging is wreaking havoc for patients and creates liability issues for hospital pharmacies, according to experts who appeared on a panel during the National Comprehensive Cancer Network (NCCN) annual meeting, which was held in a virtual format.

Number 4: Julie M. Reed, the executive director of the Biosimilars Forum, called for policies to support adoption of lower-cost biologics.

Number 3: A real-world analysis found similar safety and efficacy profiles between a biosimilar ranibizumab (Razumab) and the reference product (Lucentis, Accentrix) in Indian patients with diabetic macular edema.

Number 2: Switzerland-based company Fresenius Kabi announced that its pegfilgrastim biosimilar received marketing authorization in Europe and that it has obtained a majority stake in biosimilar manufacturer mAbxience and acquired its subsidiary.

Number 1: Republic of Korea-based Celltrion Healthcare launched its high-concentration adalimumab biosimilar in Canada and won several Brazilian tenders to supply its infliximab biosimilar.

To read all of these articles and more, visit centerforbiosimilars.com.